Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2006

View Archived Issues

GTC awarded SBIR grant for work on CD137 monoclonal antibody

Aegerion signs crosslicense agreement for MTP inhibitors

Shire reviews six months ended June 30, 2006

Wockhardt reports the antibacterial potential of their novel oxazolidinones

Rotigotine transdermal patch yields reduction in RLS symptoms

Pivotal Yondelis study in ovarian cancer recommended to continue

SIGA Technologies terminates merger agreement with PharmAthene

Valentis and Urigen sign merger agreement

Sinclair Pharma and Intendis sign marketing agreement for Atopiclair

Virax advances towards phase II trial of VIR-201 therapeutic HIV vaccine

Pfizer to acquire PowderMed

Novel antihypertensives imparted by Novartis and NitroMed

New selective dual alpha1A/1D adrenoreceptor antagonists reported by Janssen

New agents for endocrine-related disorders imparted in recent patent literature

Completion of phase II Friedreich's ataxia study of idebenone

Clinical hold lifted on CX-717

Lofexidine studied for treatment of opiate withdrawal symptoms in phase III trial

Treatment under way in BrachySil study in inoperable pancreatic cancer

Omrix and NIAID sign avian influenza CRADA

TD-5108 begins phase II for GI motility dysfunction

Can-Fite to develop CF-102 for liver cancer

Ispinesib activity modest in head and neck squamous cell carcinoma

MK-0608: a robust and durable anti-HCV candidate

Adecatumumab assessed in phase II breast and prostate cancer trials

New topoisomerase inhibitor NSC-727357 exhibits antitumor activity

PharmaMar reports clinical results for kahalalide F, plitidepsin and trabectedin

Desoxypeganine shows good pharmacokinetic profile in healthy volunteers

Preclinical data of Basilea's novel macrolide BAL-19403 presented

Grapefruit juice consumption could help to prevent osteoporosis

R&D highlights from the UBS Global Life Sciences Conference in New York: Hana Biosciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...